secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001654954-23-001927
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics reports FY2022 cash of $6.2M; plans DMT310 Phase 3 in 2H 2023
--------------------------------------------------------------------------------

- Cash and equivalents $6.2M at Dec 31, 2022, down from $10.8M a year earlier.
- R&D expenses $5.7M in FY2022 vs $3.5M in FY2021, driven by DMT310 clinical/CMC costs.
- Cash expected to fund operations into Q3 2023; no revenue reported.
- End-of-Phase 2 meeting with FDA for DMT310 (acne) expected in Q2 2023; Phase 3 start in H2 2023.
- DMT410 partnership discussions ongoing for topical botulinum toxin delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423001927/0001654954-23-001927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423001927/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-001927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer